Wafa, Ehab W.Ghoneim, Mohamed A.El-Agroudy, Amgad E.El-Baz, MahmoudGheith, Osama A.El-Husseini, AmrAbbas, Tarek M.2025-12-162009-12Experimental and Clinical Transplantation, Cilt, 7, Sayı, 4, 2009 ss. 228-2321304-0855https://hdl.handle.net/11727/14142Objectives: The aim of this retrospective study was to characterize the patients who experienced borderline rejection. Materials and Methods: Patients with a minimum follow-up of 2 years were enrolled in this study. Forty-seven patients out of 106 patients with borderline rejection (after exclusion of those with associated chronic interstitial fibrosis) were compared with patients with acute cellular rejection grade 1 (n=650), and patients free of rejection episodes (n=444) regarding the different characteristics. Results: Patients aged 20 years or younger were frequently in borderline rejection group than other groups (which was statistically significant) (P = .001). Significant differences were found in recipient and donor ages, consanguinity, pretransplant blood transfusion, and immunosuppression plan. Most patients in borderline rejection group received triple immunosuppression therapy than other groups (P = .001). Univariate and multivariate regression analysis of different variables on graft survival in borderline rejection patients revealed that none of them was statistically significant. Conclusions: Borderline rejection is a frequent finding in biopsy-proven acute rejection after kidney transplant. Time of occurrence, frequency, treatment or not, and response to therapy were not predictors to graft survival.en-USBorderline changesKidneyTransplantArticle742146-8427